With the aim of improving affordability to the patients, a generic version of anti-cancer drug olaparib has been introduced by Zydus Lifesciences of India. The reduced cost of the medicine reduces the overall cost of the treatment. Used in treatment of cancers ranging from breast, ovarian, prostate, and pancreatic, this generic medicine targets specific genetic mutations which is associated with these cancers, enabling tailored treatment.
Zydus’ Affordable Olaparib & Sigh of Relief for Indian Cancer Patients
Majority of the 1.4 million new cancer cases in India can be treatable with this medicine. Zydus hopes to address and ease the financial burden on the patients with this economical alternative. Historically, there has been a demand to reduce the high cost of original dose, and the invent of olaparib substantially improves the patient access to vital medication.
The reason why the drug could be made affordable was the expiration of certain patents, hence paving the way for the invent of affordable versions.
Patent & Their Impact on Healthcare Access
A generic olaparib launch was pioneered by Natco Pharma. This latest development in the pharma and medical world also brings forth the need for systematic evaluation of patent-related effects on healthcare access and underscores the patent impact on medicine accessibility.
Emphasizing the need to address patent-related barriers by some institutional barriers, Lawyer K. Gopakumar advocates for leveraging existing legal provisions to improve medicine access.
Speaking about the drug, then the usage of the same across stages of cancer highlights its versatility in treatment methods. This further lays importance on the fact that the drug’s affordability as well as accessibility was a major roadblock for it to truly help cancer patients across financial strata.
